• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

    2/9/22 4:05:53 PM ET
    $GMED
    Medical/Dental Instruments
    Health Care
    Get the next $GMED alert in real time by email
    SC 13G/A 1 d643534dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)*

     

     

    Globus Medical, Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    379577208

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 379577208

    Page 2 of 8

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      David C. Paul

      2.  

      Check the Appropriate Box if a Member of a Group

      Not Applicable

     

      (a)  ☐        (b)  ☐

     

      3.  

       SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.    

       Sole Voting Power

     

      429,168 (1)

       6.  

      Shared Voting Power

     

      20,867,524 (2)(3)

       7.  

      Sole Dispositive Power

     

      429,168 (1)

       8.  

      Shared Dispositive Power

     

      20,867,524 (2)(3)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      21,296,692 (2)(3)

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      21.21% (4)(5)

    12.  

      Type of Reporting Person

     

      IN

     

    (1)

    Consists of 429,168 shares of Class A common stock subject to options held by the reporting person that are exercisable within 60 days of December 31, 2021.

    (2)

    The holders of Class B common stock are entitled to 10 votes per share of Class B common stock. Each share of Class B common stock is convertible into the Issuer’s Class A common stock on a 1-for-1 basis (a) at any time at the option of the holder of such share, (b) upon the transfer of such share (subject to certain exceptions for transfers not involving a sale, such as transfers not constituting a change in beneficial ownership, estate planning transfers and gifts), and (c) if the Class B common stock held by the holder of such share plus that holder’s affiliates represents less than 5% of the Issuer’s outstanding common stock.

    (3)

    Does not include 1,562,573 shares of Class B common stock held by the Paul Family Irrevocable Trust U/A/D 4/6/10. The reporting person’s spouse is trustee of the trust.

    (4)

    Based on shares outstanding equal to: (a) 79,113,641 shares of Class A common stock outstanding as of December 31, 2021, as reported by the Issuer to the reporting person, plus (b) 429,168 shares of Class A common stock subject to options that are exercisable within 60 days of December 31, 2021, plus (c) 20,867,524 shares of Class B common stock, which are treated as converted into Class A common stock for the purpose of computing the percentage ownership of the reporting person.

    (5)

    Assumes conversion of all of the reporting person’s Class B common stock into, and exercise of all of the reporting person’s options for, shares of Class A common stock.

     

    2


    CUSIP No. 379577208

    Page 3 of 8

     

      1.    

      Name of Reporting Person

      I.R.S. Identification No. of Above Person (Entities Only)

     

      Sonali Paul

      2.  

      Check the Appropriate Box if a Member of a Group

      Not Applicable

     

      (a)  ☐        (b)  ☐

     

      3.  

       SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    with

       5.    

       Sole Voting Power

     

      1,562,573 (6)(7)

       6.  

      Shared Voting Power

     

      20,867,524 (7)(8)

       7.  

      Sole Dispositive Power

     

      1,562,573 (6)(7)

       8.  

      Shared Dispositive Power

     

       20,867,524 (7)(8)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      22,430,097 (7)(8)

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      22.09% (9)(10)

    12.  

      Type of Reporting Person

     

      IN

     

    (6)

    Consists of 1,562,573 shares of Class B common stock held by the Paul Family Irrevocable Trust U/A/D 4/6/10.

    (7)

    The holders of Class B common stock are entitled to 10 votes per share of Class B common stock. Each share of Class B common stock is convertible into the Issuer’s Class A common stock on a 1-for-1 basis (a) at any time at the option of the holder of such share, (b) upon the transfer of such share (subject to certain exceptions for transfers not involving a sale, such as transfers not constituting a change in beneficial ownership, estate planning transfers and gifts), and (c) if the Class B common stock held by the holder of such share plus that holder’s affiliates represents less than 5% of the Issuer’s outstanding common stock.

    (8)

    Does not include 429,168 shares of Class A common stock subject to options held by the reporting person’s spouse that are exercisable within 60 days of December 31, 2021.

    (9)

    Based on shares outstanding equal to: (a) 79,113,641 shares of Class A common stock outstanding as of December 31, 2021, as reported by the Issuer to the reporting person, plus (b) 22,430,097 shares of Class B common stock, which are treated as converted into Class A common stock for the purpose of computing the percentage ownership of the reporting person.

    (10)

    Assumes conversion of all of the reporting person’s Class B common stock into shares of Class A common stock.

     

    3


    CUSIP No. 379577208

    Page 4 of 8

     

    Item 1(a)

    Name of Issuer

    Globus Medical, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices

    2560 General Armistead Avenue

    Audubon, PA 19403

     

    Item 2(a)

    Name of Person Filing

    This Amendment No. 9 to Schedule 13G is being filed by David C. Paul and Sonali Paul (together, the “Reporting Persons”).

     

    Item 2(b)

    Address of Principal Business Office, or if none, Residence

    2560 General Armistead Avenue

    Audubon, PA 19403

     

    Item 2(c)

    Citizenship

    The Reporting Persons are citizens of the United States of America.

     

    Item 2(d)

    Title of Class of Securities

    Class A Common Stock

     

    Item 2(e)

    CUSIP Number

    379577208

     

    4


    CUSIP No. 379577208

    Page 5 of 8

     

    Item 3.

    Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

    Not Applicable

     

    Item 4.

    Ownership

    Ownership information is provided as of December 31, 2021:

     

    (a)

       Amount beneficially owned:   
       (i)   David C. Paul      21,296,692  (11)(12)(13)(14) 
       (ii)   Sonali Paul      22,430,097  (12)(14)(15)(16) 

    (b)

       Percent of class:   
       (i)   David C. Paul      21.21 % (17)(18) 
       (ii)   Sonali Paul      22.09 % (19)(20) 

    (c)

       Number of shares as to which such person has:   
       (i)   Sole power to vote or to direct the vote   
         (A) David C. Paul      429,168  (11)(12) 
         (B) Sonali Paul      1,562,573  (12)(15) 
       (ii)   Shared power to vote or to direct the vote   
         (A) David C. Paul      20,867,524  (12)(13)(14) 
         (B) Sonali Paul      20,867,524  (12)(14) 
       (iii)   Sole power to dispose or to direct the disposition of   
         (A) David C. Paul      429,168  (11)(12) 
         (B) Sonali Paul      1,562,573  (12)(15) 
       (iv)   Shared power to dispose or to direct the disposition of   
         (A) David C. Paul      20,867,524  (12)(13)(14) 
         (B) Sonali Paul      20,867,524  (12)(14) 

     

    (11)

    Includes 429,168 shares of Class A common stock subject to options held by the reporting person that are exercisable within 60 days of December 31, 2021.

     

    5


    CUSIP No. 379577208

    Page 6 of 8

     

    (12)

    The holders of Class B common stock are entitled to 10 votes per share of Class B common stock. Each share of Class B common stock is convertible into the Issuer’s Class A common stock on a 1-for-1 basis (a) at any time at the option of the holder of such share, (b) upon the transfer of such share (subject to certain exceptions for transfers not involving a sale, such as transfers not constituting a change in beneficial ownership, estate planning transfers and gifts), and (c) if the Class B common stock held by the holder of such share plus that holder’s affiliates represents less than 5% of the Issuers outstanding common stock.

    (13)

    Does not include 1,562,573 shares of Class B common stock held by the Paul Family Irrevocable Trust U/A/D 4/6/10. The shares are held in trust for the benefit of the reporting person’s spouse and children. The reporting person’s spouse is trustee of the trust.

    (14)

    Includes 20,867,524 shares of Class B common stock held directly by the reporting person and the reporting person’s spouse.

    (15)

    Includes 1,562,573 shares of Class B common stock held by the Paul Family Irrevocable Trust U/A/D 4/6/10.

    (16)

    Does not include 429,168 shares of Class A common stock subject to options held by the reporting person’s spouse that are exercisable within 60 days of December 31, 2021.

    (17)

    Based on shares outstanding equal to: (a) 79,113,641 shares of Class A common stock outstanding as of December 31, 2021, as reported by the Issuer to the reporting person, plus (b) 429,168 shares of Class A common stock subject to options that are exercisable within 60 days of December 31, 2021, plus (c) 20,867,524 shares of Class B common stock, which are treated as converted into Class A common stock for the purpose of computing the percentage ownership of the reporting person.

    (18)

    Assumes conversion of all of the reporting person’s Class B common stock into, and exercise of all of the reporting person’s options for, shares of Class A common stock.

    (19)

    Based on shares outstanding equal to: (a) 79,113,641 shares of Class A common stock outstanding as of December 31, 2021, as reported by the Issuer to the reporting person, plus (b) 22,430,097 of shares of Class B common stock, which are treated as converted into Class A common stock for the purpose of computing the percentage ownership of the reporting person.

    (20)

    Assumes conversion of all of the reporting person’s Class B common stock into shares of Class A common stock.

     

    6


    CUSIP No. 379577208

    Page 7 of 8

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not Applicable

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group

    Not Applicable

     

    Item 10.

    Certification

    Not Applicable

     

    7


    CUSIP No. 379577208

    Page 8 of 8

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2022

     

    /s/ David C. Paul

    David C. Paul

    /s/ Sonali Paul

    Sonali Paul

     

    8

    Get the next $GMED alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMED

    DatePrice TargetRatingAnalyst
    1/10/2025$97.00Underperform → Neutral
    BofA Securities
    12/2/2024$83.00 → $100.00Equal-Weight → Overweight
    Morgan Stanley
    8/7/2024$60.00 → $78.00Equal Weight → Overweight
    Wells Fargo
    5/20/2024$60.00 → $80.00Neutral → Overweight
    Piper Sandler
    3/18/2024$60.00Neutral → Buy
    BTIG Research
    10/20/2023$75.00Buy
    ROTH MKM
    9/19/2023$61.00Hold → Buy
    Stifel
    3/30/2023$67.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $GMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Davidar David D

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:18:17 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Deford John A

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:15:42 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Douglas Robert Andrew

      4 - GLOBUS MEDICAL INC (0001237831) (Issuer)

      3/28/25 7:13:33 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    SEC Filings

    See more
    • SEC Form 10-Q filed by Globus Medical Inc.

      10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 5:19:05 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GLOBUS MEDICAL INC (0001237831) (Filer)

      5/8/25 4:16:28 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Globus Medical Inc.

      DEFA14A - GLOBUS MEDICAL INC (0001237831) (Filer)

      4/25/25 4:24:50 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Financials

    Live finance-specific insights

    See more

    $GMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/14/24 4:08:54 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 5:06:16 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Globus Medical Inc. (Amendment)

      SC 13G/A - GLOBUS MEDICAL INC (0001237831) (Subject)

      2/13/24 4:05:32 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Reports First Quarter 2025 Results

      AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share ("EPS") was $0.54 and non-GAAP diluted EPS was $0.68 "Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine busine

      5/8/25 4:15:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical Schedules First Quarter Earnings Release and Conference Call

      AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical's website at https://www.investors.globusmedical.com/news-events/events-webcast

      4/17/25 4:30:00 PM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical completes acquisition of Nevro Corp.

      AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to patients suffering from chronic pain," said Dan Scavilla, president and CEO of Globus Medical. The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal

      4/3/25 8:31:24 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Globus Medical upgraded by BofA Securities with a new price target

      BofA Securities upgraded Globus Medical from Underperform to Neutral and set a new price target of $97.00

      1/10/25 8:55:48 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Globus Medical from Equal-Weight to Overweight and set a new price target of $100.00 from $83.00 previously

      12/2/24 6:57:12 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care
    • Globus Medical upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Globus Medical from Equal Weight to Overweight and set a new price target of $78.00 from $60.00 previously

      8/7/24 6:47:39 AM ET
      $GMED
      Medical/Dental Instruments
      Health Care

    $GMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

      MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

      11/11/21 7:26:31 PM ET
      $BEAT
      $GMED
      $GTHX
      $HOLX
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Electronics
    • Axonics® Announces Appointment of David M. Demski to Board of Directors

      IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren

      12/14/20 8:00:00 AM ET
      $AXNX
      $GMED
      Medical/Dental Instruments
      Health Care